State Street Corp Has $29.19 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)

State Street Corp decreased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 3.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,782,883 shares of the biotechnology company’s stock after selling 90,352 shares during the quarter. State Street Corp owned approximately 5.62% of REGENXBIO worth $29,192,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Louisiana State Employees Retirement System raised its position in shares of REGENXBIO by 14.0% in the second quarter. Louisiana State Employees Retirement System now owns 22,800 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 2,800 shares during the period. Bank of New York Mellon Corp raised its holdings in REGENXBIO by 9.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company’s stock valued at $3,972,000 after acquiring an additional 28,846 shares during the period. Principal Financial Group Inc. lifted its position in REGENXBIO by 4.3% during the second quarter. Principal Financial Group Inc. now owns 225,417 shares of the biotechnology company’s stock worth $2,637,000 after acquiring an additional 9,206 shares during the last quarter. Maryland State Retirement & Pension System boosted its holdings in shares of REGENXBIO by 7.2% during the second quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock worth $185,000 after acquiring an additional 1,067 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of REGENXBIO by 8.2% during the second quarter. Rhumbline Advisers now owns 118,526 shares of the biotechnology company’s stock worth $1,387,000 after purchasing an additional 8,987 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Trading Up 2.8 %

RGNX stock opened at $7.62 on Friday. The stock has a 50-day moving average price of $9.58 and a 200-day moving average price of $11.17. REGENXBIO Inc. has a 1-year low of $7.21 and a 1-year high of $28.80. The firm has a market cap of $377.53 million, a PE ratio of -1.51 and a beta of 1.24.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on RGNX shares. Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price target on shares of REGENXBIO in a research note on Wednesday, December 11th. HC Wainwright decreased their price target on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Raymond James reiterated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. Morgan Stanley reissued an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Finally, StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $35.27.

Insider Transactions at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at $114,101.46. This represents a 46.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 13.13% of the company’s stock.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.